|
108
|
345
|
4qp4A |
Crystal structure of erk2 in complex with n-cyclohexyl-9h-purin-6-amine |
|
91
|
322
|
4rj4A |
Egfr kinase (t790m/l858r) with inhibitor compound 6 |
|
97
|
285
|
4qmtA |
Mst3 in complex with hesperadin |
|
89
|
263
|
4rg0A |
Crystal structure of btk kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]-2-methyl-propanenitrile |
|
81
|
284
|
4rrvA |
Crystal structure of pdk1 in complex with atp and piftide |
|
95
|
334
|
4ra5A |
Human protein kinase c theta in complex with ligand compound 11a (6-[(1,3-dimethyl-azetidin-3-yl)-methyl-amino]-4(r)-methyl-7-phenyl-2,10-dihydro-9-oxa-1,2,4a-triaza-phenanthren-3-one) |
|
69
|
281
|
4riyA |
Crystal structure of an egfr/her3 kinase domain heterodimer containing the cancer-associated her3-e909g mutation |
|
70
|
281
|
4riwA |
Crystal structure of an egfr/her3 kinase domain heterodimer |
|
82
|
278
|
4qyfA |
Chk1 kinase domain in complex with aminopyrazine compound 13 |
|
71
|
297
|
4riwB |
Crystal structure of an egfr/her3 kinase domain heterodimer |
|
95
|
290
|
4qmpA |
Mst3 in complex with cdk1/2 inhibitor iii, 5-amino-3-{[4-(aminosulfonyl)phenyl]amino}-n-(2,6-difluorophenyl)-1h-1,2,4-triazole-1-carbothioamide |
|
87
|
299
|
4qqjA |
Crystal structure of fgf receptor (fgfr) 4 kinase domain harboring the v550l gate-keeper mutation |
|
84
|
335
|
4ra4A |
Crystal structure of human protein kinase c alpha in complex with compound 28 ((r)-6-((3s,4s)-1,3-dimethyl-piperidin-4-yl)-7-(2-fluoro-phenyl)-4-methyl-2,10-dihydro-9-oxa-1,2,4a-triaza-phenanthren-3-one) |
|
80
|
273
|
4rpvA |
Co-crystal structure of pim1 with compound 3 |
|
114
|
327
|
4rlkA |
Crystal structure of z. mays ck2alpha in complex with the atp-competitive inhibitor 4-[(e)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoate |
|
105
|
349
|
4qp3A |
Crystal structure of erk2 in complex with (s)-2-((9h-purin-6-yl)amino)-3-phenylpropan-1-ol |
|
95
|
291
|
4r1vA |
Identification and optimization of pyridazinones as potent and selective c-met kinase inhibitors |
|
92
|
322
|
4rj7A |
Egfr kinase (t790m/l858r) with inhibitor compound 1 |
|
101
|
349
|
4qp6A |
Crystal structure of erk2 in complex with 5h-pyrrolo[2,3-b]pyrazine |
|
92
|
289
|
4qmoA |
Mst3 in complex with imidazolo-oxindole pkr inhibitor c16 |
|
111
|
349
|
4qtaA |
Structure of human erk2 in complex with sch772984 revealing a novel inhibitor-induced binding pocket |
|
76
|
273
|
4rc3A |
Crystal structure of ser/thr kinase pim1 in complex with mitoxantrone derivatives |
|
87
|
286
|
4rqkA |
Crystal structure of pdk1 in complex with atp and the pif-pocket ligand rs1 |
|
104
|
287
|
4r7bA |
Crystal structure of pneumococcal lica in complex with choline |
|
74
|
272
|
4r5yA |
The complex structure of braf v600e kinase domain with a novel braf inhibitor |
|
90
|
285
|
4rioA |
Crystal structure of jak3 kinase domain in complex with a pyrrolopyridazine carboxamide inhibitor |
|
115
|
349
|
4r3cA |
Crystal structure of p38 alpha map kinase in complex with a novel isoform selective drug candidate |
|
95
|
285
|
4r77A |
Crystal structure of choline kinase lica from streptococcus pneumoniae |
|
97
|
289
|
4qmvA |
Mst3 in complex with pf-03814735, n-{2-[(1s,4r)-6-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl]-2-oxoethyl}acetamide |
|
80
|
278
|
4qyeA |
Chk1 kinase domain in complex with diarylpyrazine compound 1 |
|
87
|
289
|
4qt1A |
Jak3 kinase domain in complex with 1-[(3s)-1-isobutylsulfonyl-3-piperidyl]-3-(5h-pyrrolo[2,3-b]pyrazin-2-yl)urea |
|
122
|
351
|
4qtbA |
Structure of human erk1 in complex with sch772984 revealing a novel inhibitor-induced binding pocket |
|
82
|
263
|
4rfmA |
Itk kinase domain in complex with compound 1 n-{1-[(1,1-dioxo-1-thian-2-yl)(phenyl)methyl]-1h- pyrazol-4-yl}-5,5-difluoro-5a-methyl-1h,4h,4ah,5h,5ah,6h-cyclopropa[f]indazole-3-carboxamide |
|
91
|
346
|
4qpaA |
Crystal structure of erk2 in complex with 7-(1-benzyl-1h-pyrazol-4-yl)-2-(pyridin-4-yl)-5h-pyrrolo[2,3-b]pyrazine |
|
75
|
273
|
4rblA |
Crystal structure of ser/thr kinase pim1 in complex with mitoxantrone derivatives |
|
102
|
349
|
4qp2A |
Crystal structure of erks in complex with 5-chlorobenzo[d]oxazol-2-amine |
|
86
|
308
|
4r6vA |
Crystal structure of fgf receptor (fgfr) 4 kinase harboring the v550l gate-keeper mutation in complex with fiin-3, an irreversible tyrosine kinase inhibitor capable of overcoming fgfr kinase gate-keeper mutations |
|
88
|
322
|
4r5sA |
Crystal structure of egfr 696-1022 l858r in complex with fiin-3 |
|
93
|
281
|
4qo9A |
Mst3 in complex with danusertib |
|
99
|
289
|
4qmmA |
Mst3 in complex with at-9283, 4-[(2-{4-[(cyclopropylcarbamoyl)amino]-1h-pyrazol-3-yl}-1h-benzimidazol-6-yl)methyl]morpholin-4-ium |
|
90
|
285
|
4qnaA |
Mst3 in complex with 2-(4,6-diamino-1,3,5-triazin-2-yl)phenol |
|
86
|
289
|
4rqvA |
Crystal structure of pdk1 in complex with atp and the pif-pocket ligand rs2 |
|
106
|
329
|
4rllA |
Crystal structure of human ck2alpha in complex with the atp-competitive inhibitor 4-[(e)-(fluoren-9-ylidenehydrazinylidene)-methyl] benzoate |
|
105
|
346
|
4qp8A |
Crystal structure of erk2 in complex with 2-(1h-pyrazol-4-yl)-7-(pyridin-3-yl)-5h-pyrrolo[2,3-b]pyrazine |
|
82
|
285
|
4r1yA |
Identification and optimization of pyridazinones as potent and selective c-met kinase inhibitor |
|
79
|
271
|
4qygA |
Chk1 kinase domain in complex with diazacarbazole compound 14 |
|
100
|
287
|
4qmzA |
Mst3 in complex with sunitinib |
|
53
|
168
|
4q5eA |
Shigella effector kinase ospg bound to e2-ub ubch7-ub conjugate |
|
87
|
281
|
4qmlA |
Mst3 in complex with amp-pnp |
|
114
|
330
|
4qtcA |
Structure of human haspin (gsg2) in complex with sch772984 revealing the first type-i binding mode |
